Systematic review and meta-analysis of the efficacy of dabrafenib and trametinib in the multi-modal treatment of anaplastic thyroid cancer.

IF 0.8 4区医学 Q3 OTORHINOLARYNGOLOGY Journal of Laryngology and Otology Pub Date : 2025-06-01 DOI:10.1017/S0022215124001166

Aaron Limonard, James Zhang, James Inchley, Audrey Yap, Victor Yan Zhe Lu, Neil Tolley

{"title":"Systematic review and meta-analysis of the efficacy of dabrafenib and trametinib in the multi-modal treatment of anaplastic thyroid cancer.","authors":"Aaron Limonard, James Zhang, James Inchley, Audrey Yap, Victor Yan Zhe Lu, Neil Tolley","doi":"10.1017/S0022215124001166","DOIUrl":null,"url":null,"abstract":"Objectives: This study analyses the current literature to evaluate the effectiveness of dabrafenib and trametinib in the multi-modal treatment of anaplastic thyroid cancer (ATC).Method: A systematic review and meta-analysis of the literature were undertaken. The primary endpoint measured was overall response rate (ORR) defined by the RECIST v1.1 guidelines. Secondary endpoints were 12-month overall survival (OS), median OS and progression-free survival (PFS).Results: Of 656 identified reports, 8 studies were included which featured 95 patients (median age 68.5 years, 46 per cent male). Median follow-up period was 11.8 months with a 12-month OS of 51 per cent. Median OS was 10.4 months. Progression-free survival (PFS) was 6.5 months. The ORR was 71 per cent. A total of 65 patients exhibited a partial or complete response in radiological tumour size. Side effects compared favourably to other kinase inhibitors.Conclusion: Dabrafenib and trametinib exhibit a promising tumour response with a tolerable side profile. BRAF/MEK inhibitors continue to provide robust responses in BRAF-mutated ATC. The heterogeneity and lack of controls in included studies limits the confidence in the conclusions drawn.","PeriodicalId":16293,"journal":{"name":"Journal of Laryngology and Otology","volume":" ","pages":"441-450"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Laryngology and Otology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S0022215124001166","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study analyses the current literature to evaluate the effectiveness of dabrafenib and trametinib in the multi-modal treatment of anaplastic thyroid cancer (ATC).

Method: A systematic review and meta-analysis of the literature were undertaken. The primary endpoint measured was overall response rate (ORR) defined by the RECIST v1.1 guidelines. Secondary endpoints were 12-month overall survival (OS), median OS and progression-free survival (PFS).

Results: Of 656 identified reports, 8 studies were included which featured 95 patients (median age 68.5 years, 46 per cent male). Median follow-up period was 11.8 months with a 12-month OS of 51 per cent. Median OS was 10.4 months. Progression-free survival (PFS) was 6.5 months. The ORR was 71 per cent. A total of 65 patients exhibited a partial or complete response in radiological tumour size. Side effects compared favourably to other kinase inhibitors.

Conclusion: Dabrafenib and trametinib exhibit a promising tumour response with a tolerable side profile. BRAF/MEK inhibitors continue to provide robust responses in BRAF-mutated ATC. The heterogeneity and lack of controls in included studies limits the confidence in the conclusions drawn.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

达非尼和曲美替尼多模式治疗间变性甲状腺癌疗效的系统评价和荟萃分析。

目的：本研究通过对现有文献的分析，评价达非尼与曲美替尼在多模式治疗间变性甲状腺癌（ATC）中的疗效。方法：对相关文献进行系统回顾和荟萃分析。测量的主要终点是由RECIST v1.1指南定义的总缓解率（ORR）。次要终点为12个月总生存期（OS）、中位OS和无进展生存期（PFS）。结果：在656份确定的报告中，纳入了8项研究，其中包括95名患者（中位年龄68.5岁，46%为男性）。中位随访期为11.8个月，12个月的OS为51%。中位OS为10.4个月。无进展生存期（PFS）为6.5个月。ORR为71%。65例患者在放射学肿瘤大小方面表现出部分或完全缓解。与其他激酶抑制剂相比，副作用较好。结论：达非尼和曲美替尼表现出有希望的肿瘤反应和可耐受的副作用。BRAF/MEK抑制剂继续在BRAF突变的ATC中提供稳健的应答。纳入研究的异质性和缺乏对照限制了得出结论的可信度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Laryngology and Otology 医学-耳鼻喉科学

CiteScore

3.20

自引率

11.80%

发文量

593

审稿时长

3-6 weeks

期刊介绍： The Journal of Laryngology & Otology (JLO) is a leading, monthly journal containing original scientific articles and clinical records in otology, rhinology, laryngology and related specialties. Founded in 1887, JLO is absorbing reading for ENT specialists and trainees. The journal has an international outlook with contributions from around the world, relevant to all specialists in this area regardless of the country in which they practise. JLO contains main articles (original, review and historical), case reports and short reports as well as radiology, pathology or oncology in focus, a selection of abstracts, book reviews, letters to the editor, general notes and calendar, operative surgery techniques, and occasional supplements. It is fully illustrated and has become a definitive reference source in this fast-moving subject area. Published monthly an annual subscription is excellent value for money. Included in the subscription is access to the JLO interactive web site with searchable abstract database of the journal archive back to 1887.